Capricor shares tumble after US FDA rejects cell therapy, citing trial violations
Capricor said the US Food and Drug Administration rejected its cell-therapy application, triggering an sharp fall in its share price.
YieldTimes Markets Desk 1 min read

Capricor’s (NASDAQ: CAPR) shares plunged by around 80% after the US Food and Drug Administration rejected its cell therapy, with the regulator citing violations related to a clinical trial.
The FDA’s decision marks a major setback for the company’s development programme. Seeking Alpha reported that Capricor was reviewing its operations following the rejection.
In the wake of the decision, investors reassessed the near-term prospects for the company’s lead programme and the strength of its clinical-compliance approach. For markets, regulatory outcomes like this can materially affect sentiment across biotech, especially for firms dependent on trial milestones and upcoming submissions for continued funding and partnerships.
Cell therapies face heightened scrutiny because manufacturing controls and trial conduct must meet stringent requirements. When regulators identify trial-related issues, companies often need to address the deficiencies, potentially restarting or redesigning elements of their clinical strategy, before resubmitting.
For Capricor, the immediate implications are operational. The company indicated it would be reviewing operations after the FDA rejection, suggesting internal process changes may be needed to align with regulatory expectations.
From a sector perspective, the episode underscores how regulatory timing can dominate stock performance in development-stage biotech. While the FDA’s ruling is the key event, the longer-term question will be what Capricor does next to remedy the cited trial violations and how that affects future regulatory interactions.
Risks remain elevated for any follow-up plan: addressing regulatory concerns can take time, may require additional clinical work, and can further delay potential approvals. On the other hand, a structured response to regulator feedback could help clarify a path forward for the programme.
What to watch
- Any updates from Capricor on the operational review and remediation steps following the FDA decision.
- Whether Capricor outlines plans to address the trial violations cited by the regulator.
- Timing and details of any future regulatory engagement or resubmission strategy.
- Continued market reaction as investors reprice biotech regulatory risk.
For information only, not financial advice. This article reports market news and does not recommend buying or selling any security. See the disclaimer.
More from Stocks
All →US Senate clears bipartisan permitting bill for energy projects, with House vote next month
Treasury secretary says no further limits on Nvidia chip sales to China as California probe broadens
Amazon close to US$7.5B acquisition of AI start-up Decart, report says
Several US-listed shares fall to new 52-week lows